Arkolith/Insider Trading/ORMP/Form 4

Kidron Nadav

President and CEO, DirectorORAMED PHARMACEUTICALS INC. (ORMP) · full profile →Form 4 · filed Jan 5, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Dec 31, 2025Grant(A)327K—$03.2M
Dec 31, 2025Grant(A)233K—$02.9M

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Dec 31, 2025Grant(A)109K—$0109K

Transaction Codes

A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001213900-26-001280) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML